Global Blood Clotting Factor Market Analysis and Value Forecast Snapshot by End-use Industry 2026


Posted December 13, 2019 by DatabridgeMR

Global Blood Clotting Factor Market Analysis and Value Forecast Snapshot by End-use Industry 2026

 
Market Analysis: Global Blood Clotting Factor Market

Global blood clotting factor market is estimated to rise with the substantial CAGR in the forecast period of 2019 to 2026. The imminent market report contains data for historic year 2017 and the base year calculation is 2018 and the forecast period is 2019 to 2026.The growth of the market can be attributed to prevalence of acute stroke and short window for treatment of stroke.

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-blood-clotting-factor-market

Market Definition: Global Blood Clotting Factor Market

Blood coagulation or coagulation is the method through which blood shifts from liquid to gel, creating clots. These clots lead to bleeding cessation. However, in individuals with liver disease, thrombophilia, and hemophilia, the coagulation process is hindered. Different testing processes for blood coagulation are used to diagnose these illnesses, which provide the hemostatic functioning status of the patients

600,000 non-fatal cases of deadly blood clots occur each year, of which 40% are blood clots in the lungs and 60% are blood clots in the legs

900,000 cases per year are now suggested by recent scientific modeling and public health statistics.

Market Drivers

Rising incidence of cardiovascular diseases and blood disorders is driving the market growth
Increasing condition of high-sensitivity POC coagulation testing will propel the growth of the market
Advancement in technology is boosting the market growth in the forecast period
Rising laboratory automation can fuel the growth of the market

Market Restraints

Excessive cost of fully automated coagulation analyzer will hinder the growth of the market
Less  availability of skilled professional is also hampering the market in the forecast period
Strict government rules & regulations regarding with the safety and efficiency of blood clot retrieval devices is restraining the market growth

Key Market Competitors:

Some of the major companies functioning in global blood clotting factor market are Novartis AG, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., BioreclamationIVT. ELEVATING SCIENCE, Life Technologies, Illumina, Inc., Agilent Technologies,Inc, GENERAL ELECTRIC, Perkinelmer, Inc., QIAGEN, Oxford Gene Technology, Pacific Biosciences of California, Inc., BGI, Eurofins Scientific, Quest Diagnostics Incorporated,  Novogene Corporation, Promega Corporation, Luminex Corporation, TAKARA BIO INC, Danaher, ELITechGroup, MYRIAD GENETICS, INC, AutoGenomics, Biocartis, IntegraGen and Interpace Diagnostics group, inc, among others

Segmentation: Global Blood Clotting Factor Market

By Product

Clinical Laboratory Analyzers
Consumables
Systems
Automated Systems
Semi-automated Systems
Manual Systems
Point-Of-Care Testing Analyzers

By  Test

Prothrombin Time Testing
Fibrinogen Testing
Activated Partial Thromboplastin Time Testing
Activated Clotting Time Testing
D-Dimer Testing
Platelet Function Tests
Anti-Factor Xa Tests
Heparin & Protamine Dose Response Tests for ACT
Others

By Technology

Mechanical Technology
Optical Technology
Electrochemical Technology
Others

By Application

Bleeding Disorder
Acquired Bleeding Disorders
Hemophilia
Von Willebrand Disease

By End User

Academic Institutions
Hospitals
Diagnostic Laboratories

By Geography

North America
U.S.
Canada
Mexico
South America
Brazil
Rest of South America
Europe
Germany
Italy
U.K.
France
Spain
Netherlands
Belgium
Switzerland
Turkey
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
South Korea
Indonesia
Malaysia
Australia
Singapore
Thailand
Philippines
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East & Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-blood-clotting-factor-market

Key Developments in the Market:

In October 2018, Genentech a member of Roche group received FDA approval for the drug Hemlibra. This product will help in prevention of bleeding episodes in adults and children. With this approval the company had increase its brand value in the market
In February, 2018, Novo Nordisk received approval for its product NovoSeven RT. The product is able to act as anti-coagulating agent which will assist the company to enhance its product portfolio in the market

Competitive Analysis:

Global blood clotting factor market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of blood clotting factor market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By DBMR
Country India
Categories Blogging
Tags global blood clotting factor market
Last Updated December 13, 2019